CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for bioAffinity Technologies Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

bioAffinity Technologies Inc
22211 West Interstate-10, Suite 1206
Phone: (210) 698-5334p:210 698-5334 SAN ANTONIO, TX  78257  United States Ticker: BIAFBIAF
Business Summary
bioAffinity Technologies, Inc. is a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease. The Company addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostic tests using flow cytometry and automated analysis developed by artificial intelligence (AI). Its diagnostic tests analyze cell populations, including cancer and cancer-related cells, that are indicative of a specific diseased state. Its first product, CyPath Lung, is a noninvasive test that addresses the need for noninvasive detection of early-stage lung cancer. The CyPath Lung test enables physicians to identify patients who will likely benefit from timely intervention and more invasive follow-up procedures and those who are likely without lung cancer and should continue routine screening. CyPath Lung is marketed as a Laboratory Developed Test.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board StevenGirgenti 77 3/1/2014 3/1/2014
President, Chief Executive Officer, Founder, Director MariaZannes 67 3/1/2014 3/1/2014
Chief Financial Officer, Principal Accounting Officer, Vice President MichaelDougherty 44 5/1/2023 5/1/2023
7 additional Officers and Directors records available in full report.

Business Names
Business Name
BIAF
Precision Pathology Laboratory Services, LLC

General Information
Number of Employees: 75 (As of 12/31/2023)
Outstanding Shares: 11,514,354 (As of 3/20/2024)
Shareholders: 79
Stock Exchange: NASD
Federal Tax Id: 465211056
Fax Number: (916) 443-1908


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024